In Brief: Life Medical Sciences
This article was originally published in The Gray Sheet
Executive Summary
Life Medical Sciences: Company focusing development efforts on Repel bioresorable gel for adhesion prevention following early termination of its Piliel hair regrowth European clinical trial for the topical gel product. The company says it will submit an investigational device exemption to initiate U.S. trials of Repel-CV, a bioresorbable film designed to prevent post-operative adhesions following cardiovascular surgery. Data from a U.S. pilot study of the firm's Repel bioresorbable film for use in gynecological surgery show the product was "twice as effective in reducing adhesion formation compared to the control of standard surgical treatment." The device was particularly effective in treating adhesion formation on the posterior surface of the uterus. The company plans to seek FDA go-ahead for a pivotal trial in the U.S...
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.